View Financial HealthBaijin Life Science Holdings 배당 및 자사주 매입배당 기준 점검 0/6Baijin Life Science Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-2.6%자사주 매입 수익률총 주주 수익률-2.6%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 19Baijin Life Science Holdings Limited to Report Fiscal Year 2026 Final Results on Jun 30, 2026Baijin Life Science Holdings Limited announced that they will report fiscal year 2026 final results at 12:30 PM, China Standard Time on Jun 30, 2026공고 • Nov 17Baijin Life Science Holdings Limited to Report First Half, 2026 Results on Nov 27, 2025Baijin Life Science Holdings Limited announced that they will report first half, 2026 results on Nov 27, 2025공고 • Sep 30Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 19.2 million.Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 19.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing공고 • Aug 21Baijin Life Science Holdings Limited, Annual General Meeting, Sep 30, 2025Baijin Life Science Holdings Limited, Annual General Meeting, Sep 30, 2025, at 11:00 China Standard Time. Location: unit d, 8/f, kingston international centre, 19 wang chiu road, kowloon bay, Hong Kong공고 • Jul 15Baijin Life Science Holdings Limited to Report Fiscal Year 2025 Final Results on Jul 25, 2025Baijin Life Science Holdings Limited announced that they will report fiscal year 2025 final results on Jul 25, 2025공고 • Jun 09Baijin Life Science Holdings Limited to Report Fiscal Year 2025 Results on Jun 30, 2025Baijin Life Science Holdings Limited announced that they will report fiscal year 2025 results on Jun 30, 2025공고 • Apr 03Baijin Life Science Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 31.372528 million.Baijin Life Science Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 31.372528 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,359,433 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing공고 • Mar 18Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 31.372528 million.Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 31.372528 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,359,433 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing공고 • Nov 19Affluent Partners Holdings Limited to Report First Half, 2025 Results on Nov 29, 2024Affluent Partners Holdings Limited announced that they will report first half, 2025 results on Nov 29, 2024공고 • Aug 29Affluent Partners Holdings Limited, Annual General Meeting, Sep 30, 2024Affluent Partners Holdings Limited, Annual General Meeting, Sep 30, 2024, at 11:00 China Standard Time. Location: units 5906-12, 59/f, the center, 99 queen`s road central, central, Hong Kong공고 • Jun 26Affluent Partners Holdings Limited to Report Fiscal Year 2024 Results on Jul 19, 2024Affluent Partners Holdings Limited announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Jul 19, 2024공고 • Mar 27Affluent Partners Holdings Limited Announces Changes to Its Board and CommitteesThe Board of Affluent Partners Holdings Limited announced that, with effect on 26 March 2024, Dr. Su Yaoyao has been appointed as an executive Director of the Company, one of the Authorised Representatives and Process Agent. Dr. Su, aged 41, has been the general manager of Beijing Baijing Biotechnology Company Limited since March 2022 and was the general manager of Hangzhou Qingda Kerui Biological Technology Co. Ltd. from September 2018 to March 2022. Dr. Su graduated from Southeast University with a bachelor's degree in public health and PhD degree in public health in 2006 and 2012 respectively. The Board further announced that Mr. Cheng Chi Kin ("Mr. Cheng''), the Chairman of the Board and an executive Director, has resigned from his role as Chairman and re-designated as a non-executive Director with effect from 26 March 2024, due to his other business commitments. Mr. Cheng has also resigned as a member of the Remuneration Committee and Nomination Committee of the Board, and will cease to act as one of the Authorised Representatives and the Process Agent on the same date. Mr. Cheng Chi Kin, aged 55, was appointed as an executive director and the Chairman of the Board of the Company on 27 September 2019 and 18 October 2019 respectively. He obtained a Degree in Business Studies from University of Glamorgan in 1992 and a Master Degree in Business Administration from Cardiff Business School in 1993. He is a fellow member of Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of International Accountants. He is also a Chartered Marketer of The Chartered Institute of Marketing and a member of Institute of Management Accountants. He has over 28 years of working experience in merger and acquisition, finance and accounting, banking, asset management and funds operations in various industries including real estate developments, infrastructure developments, real estate investment trusts (REITS), securities investments and natural resources industries. Mr. Cheng was an executive director and the chief executive officer of China Uptown Group Company Limited from June 2022 to March 2024, an executive director of DeTai New Energy Group Limited from August 2021 to March 2024 and the chairman of the board of the same company from November 2021 to March 2024, and the shares of both companies are listed on the Main Board of the Stock Exchange. The Board further announced that following the appointment of Dr. Su and re-designation of Mr. Cheng, both Mr. Cheung Sze Ming, an executive Director, and Dr. Su will be appointed as members of the Remuneration Committee and Nomination Committee of the Board on 26 March 2024.공고 • Nov 29Affluent Partners Holdings Limited Announces Appointment of Lee Ka Leung Daniel as an Independent Non-Executive Director, the Chairman of the Audit Committee, A Member of the Remuneration Committee and A Member of the Nomination CommitteeThe board of directors of Affluent Partners Holdings Limited announced Mr. Lee Ka Leung Daniel has been appointed as an independent non-executive Director, the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee of the Company with effect from 29 November 2023. Mr. Lee, aged 65, is a certified public accountant with practising certificate. He is the fellow member of Hong Kong Institute of Certified Public Accountants and Association of Chartered Certified Accountants. Mr. Lee was the founder and managing partner of K. L. Lee & Partners C.P.A. Limited and KLL Associates CPA Limited which were merged with BDO Limited, Hong Kong member firm of the international accounting network BDO in 2005. Mr. Lee retired from BDO Limited as partner in 2023. Mr. Lee was a member of the Chinese People's Political Consultative Conference Hainan Committee during the period from 2013-2022. Mr. Lee was an independent non-executive director of China Credit Holdings Limited (currently named as Zensun Enterprises Limited), a company listed on The Stock Exchange of Hong Kong Limited during the period from 1994 to 2006 and China Gas Holdings Limited, a company listed on the Stock Exchange during the period from 1997 to 2003.공고 • Nov 17Affluent Partners Holdings Limited to Report First Half, 2024 Results on Nov 28, 2023Affluent Partners Holdings Limited announced that they will report first half, 2024 results on Nov 28, 2023공고 • Oct 28Affluent Partners Holdings Limited Appoints Dong Peng as Executive DirectorAffluent Partners Holdings Limited appointed Mr. Dong Peng as executive Director of the Company with effect from 27 October 2023. Mr. Dong, aged 35, occupied management roles in the fields of corporate communications and marketing in Shanghai and Shenzhen prior to joining the Company. Mr. Dong has been an investor relationship director at Shanghai Dao Zhi Information Technology Co., Limited since August 2022 and was a senior consultant of marketing department of Yunrui (Shenzhen) Information Technology Co., Limited* (()) from July 2020 to July 2022. He had served as a military officer in China for 5 years prior to working in the private sector.공고 • Jul 29Affluent Partners Holdings Limited, Annual General Meeting, Aug 30, 2023Affluent Partners Holdings Limited, Annual General Meeting, Aug 30, 2023, at 11:00 China Standard Time. Location: Units 590612, 59/F, The Center, 99 Queen's Road Central, Central Hong Kong Agenda: To receive and consider the audited financial statements and the reports of the Directors and the independent auditor of the Company for the year ended 31 March 2023; to re-elect the retiring Directors; to authorise the Board of Directors to fix the Directors' remuneration; to re-appoint Moore Stephens CPA Limited as the independent auditor of the Company and to authorise the Board of Directors to fix its remuneration; and to consider other matters.공고 • Jun 16Affluent Partners Holdings Limited to Report Fiscal Year 2023 Results on Jun 28, 2023Affluent Partners Holdings Limited announced that they will report fiscal year 2023 results on Jun 28, 2023공고 • May 11Affluent Partners Holdings Limited Announces Resignation of Chiu Sin Nang as Independent Non-Executive DirectorThe Board of Affluent Partners Holdings Limited announced that Mr. Chiu has tendered his resignation as an independent non-executive Director, the chairman of the Audit Committee, a member of the Nomination Committee and a member of the Remuneration Committee of the Company with effect from the date of this announcement as he intended to devote more time to his other business engagements. Mr. Chiu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation from the position that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MNNG.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MNNG.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Baijin Life Science Holdings 배당 수익률 vs 시장MNNG.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MNNG.F)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.0%업계 평균 (Luxury)2.4%분석가 예측 (MNNG.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MNNG.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MNNG.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MNNG.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MNNG.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/05 08:47종가2026/07/29 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Baijin Life Science Holdings Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jun 19Baijin Life Science Holdings Limited to Report Fiscal Year 2026 Final Results on Jun 30, 2026Baijin Life Science Holdings Limited announced that they will report fiscal year 2026 final results at 12:30 PM, China Standard Time on Jun 30, 2026
공고 • Nov 17Baijin Life Science Holdings Limited to Report First Half, 2026 Results on Nov 27, 2025Baijin Life Science Holdings Limited announced that they will report first half, 2026 results on Nov 27, 2025
공고 • Sep 30Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 19.2 million.Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 19.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 40,000,000 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing
공고 • Aug 21Baijin Life Science Holdings Limited, Annual General Meeting, Sep 30, 2025Baijin Life Science Holdings Limited, Annual General Meeting, Sep 30, 2025, at 11:00 China Standard Time. Location: unit d, 8/f, kingston international centre, 19 wang chiu road, kowloon bay, Hong Kong
공고 • Jul 15Baijin Life Science Holdings Limited to Report Fiscal Year 2025 Final Results on Jul 25, 2025Baijin Life Science Holdings Limited announced that they will report fiscal year 2025 final results on Jul 25, 2025
공고 • Jun 09Baijin Life Science Holdings Limited to Report Fiscal Year 2025 Results on Jun 30, 2025Baijin Life Science Holdings Limited announced that they will report fiscal year 2025 results on Jun 30, 2025
공고 • Apr 03Baijin Life Science Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 31.372528 million.Baijin Life Science Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 31.372528 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,359,433 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing
공고 • Mar 18Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 31.372528 million.Baijin Life Science Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 31.372528 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,359,433 Price\Range: HKD 0.48 Transaction Features: Subsequent Direct Listing
공고 • Nov 19Affluent Partners Holdings Limited to Report First Half, 2025 Results on Nov 29, 2024Affluent Partners Holdings Limited announced that they will report first half, 2025 results on Nov 29, 2024
공고 • Aug 29Affluent Partners Holdings Limited, Annual General Meeting, Sep 30, 2024Affluent Partners Holdings Limited, Annual General Meeting, Sep 30, 2024, at 11:00 China Standard Time. Location: units 5906-12, 59/f, the center, 99 queen`s road central, central, Hong Kong
공고 • Jun 26Affluent Partners Holdings Limited to Report Fiscal Year 2024 Results on Jul 19, 2024Affluent Partners Holdings Limited announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Jul 19, 2024
공고 • Mar 27Affluent Partners Holdings Limited Announces Changes to Its Board and CommitteesThe Board of Affluent Partners Holdings Limited announced that, with effect on 26 March 2024, Dr. Su Yaoyao has been appointed as an executive Director of the Company, one of the Authorised Representatives and Process Agent. Dr. Su, aged 41, has been the general manager of Beijing Baijing Biotechnology Company Limited since March 2022 and was the general manager of Hangzhou Qingda Kerui Biological Technology Co. Ltd. from September 2018 to March 2022. Dr. Su graduated from Southeast University with a bachelor's degree in public health and PhD degree in public health in 2006 and 2012 respectively. The Board further announced that Mr. Cheng Chi Kin ("Mr. Cheng''), the Chairman of the Board and an executive Director, has resigned from his role as Chairman and re-designated as a non-executive Director with effect from 26 March 2024, due to his other business commitments. Mr. Cheng has also resigned as a member of the Remuneration Committee and Nomination Committee of the Board, and will cease to act as one of the Authorised Representatives and the Process Agent on the same date. Mr. Cheng Chi Kin, aged 55, was appointed as an executive director and the Chairman of the Board of the Company on 27 September 2019 and 18 October 2019 respectively. He obtained a Degree in Business Studies from University of Glamorgan in 1992 and a Master Degree in Business Administration from Cardiff Business School in 1993. He is a fellow member of Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of International Accountants. He is also a Chartered Marketer of The Chartered Institute of Marketing and a member of Institute of Management Accountants. He has over 28 years of working experience in merger and acquisition, finance and accounting, banking, asset management and funds operations in various industries including real estate developments, infrastructure developments, real estate investment trusts (REITS), securities investments and natural resources industries. Mr. Cheng was an executive director and the chief executive officer of China Uptown Group Company Limited from June 2022 to March 2024, an executive director of DeTai New Energy Group Limited from August 2021 to March 2024 and the chairman of the board of the same company from November 2021 to March 2024, and the shares of both companies are listed on the Main Board of the Stock Exchange. The Board further announced that following the appointment of Dr. Su and re-designation of Mr. Cheng, both Mr. Cheung Sze Ming, an executive Director, and Dr. Su will be appointed as members of the Remuneration Committee and Nomination Committee of the Board on 26 March 2024.
공고 • Nov 29Affluent Partners Holdings Limited Announces Appointment of Lee Ka Leung Daniel as an Independent Non-Executive Director, the Chairman of the Audit Committee, A Member of the Remuneration Committee and A Member of the Nomination CommitteeThe board of directors of Affluent Partners Holdings Limited announced Mr. Lee Ka Leung Daniel has been appointed as an independent non-executive Director, the chairman of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee of the Company with effect from 29 November 2023. Mr. Lee, aged 65, is a certified public accountant with practising certificate. He is the fellow member of Hong Kong Institute of Certified Public Accountants and Association of Chartered Certified Accountants. Mr. Lee was the founder and managing partner of K. L. Lee & Partners C.P.A. Limited and KLL Associates CPA Limited which were merged with BDO Limited, Hong Kong member firm of the international accounting network BDO in 2005. Mr. Lee retired from BDO Limited as partner in 2023. Mr. Lee was a member of the Chinese People's Political Consultative Conference Hainan Committee during the period from 2013-2022. Mr. Lee was an independent non-executive director of China Credit Holdings Limited (currently named as Zensun Enterprises Limited), a company listed on The Stock Exchange of Hong Kong Limited during the period from 1994 to 2006 and China Gas Holdings Limited, a company listed on the Stock Exchange during the period from 1997 to 2003.
공고 • Nov 17Affluent Partners Holdings Limited to Report First Half, 2024 Results on Nov 28, 2023Affluent Partners Holdings Limited announced that they will report first half, 2024 results on Nov 28, 2023
공고 • Oct 28Affluent Partners Holdings Limited Appoints Dong Peng as Executive DirectorAffluent Partners Holdings Limited appointed Mr. Dong Peng as executive Director of the Company with effect from 27 October 2023. Mr. Dong, aged 35, occupied management roles in the fields of corporate communications and marketing in Shanghai and Shenzhen prior to joining the Company. Mr. Dong has been an investor relationship director at Shanghai Dao Zhi Information Technology Co., Limited since August 2022 and was a senior consultant of marketing department of Yunrui (Shenzhen) Information Technology Co., Limited* (()) from July 2020 to July 2022. He had served as a military officer in China for 5 years prior to working in the private sector.
공고 • Jul 29Affluent Partners Holdings Limited, Annual General Meeting, Aug 30, 2023Affluent Partners Holdings Limited, Annual General Meeting, Aug 30, 2023, at 11:00 China Standard Time. Location: Units 590612, 59/F, The Center, 99 Queen's Road Central, Central Hong Kong Agenda: To receive and consider the audited financial statements and the reports of the Directors and the independent auditor of the Company for the year ended 31 March 2023; to re-elect the retiring Directors; to authorise the Board of Directors to fix the Directors' remuneration; to re-appoint Moore Stephens CPA Limited as the independent auditor of the Company and to authorise the Board of Directors to fix its remuneration; and to consider other matters.
공고 • Jun 16Affluent Partners Holdings Limited to Report Fiscal Year 2023 Results on Jun 28, 2023Affluent Partners Holdings Limited announced that they will report fiscal year 2023 results on Jun 28, 2023
공고 • May 11Affluent Partners Holdings Limited Announces Resignation of Chiu Sin Nang as Independent Non-Executive DirectorThe Board of Affluent Partners Holdings Limited announced that Mr. Chiu has tendered his resignation as an independent non-executive Director, the chairman of the Audit Committee, a member of the Nomination Committee and a member of the Remuneration Committee of the Company with effect from the date of this announcement as he intended to devote more time to his other business engagements. Mr. Chiu has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation from the position that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.